

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2023, the Group is expected to record (i) a net profit in the range of RMB90 million to RMB100 million for the six months ended June 30, 2023, representing an increase of 25.9% to 39.9% as compared to that of approximately RMB71.5 million for the same period in 2022, and (ii) a profit attributable to owners of the Company in the range of RMB63 million to RMB73 million for the six months ended June 30, 2023, representing an increase of 4.0% to 20.5% as compared to that of approximately RMB60.6 million for the same period in 2022.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by PW Medtech Group Limited (the “**Company**” together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”) (as defined in the Listing Rules).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2023, the Group is expected to record (i) a net profit in the range of RMB90 million to RMB100 million for the six months ended June 30, 2023, representing an increase of 25.9% to 39.9% as compared to that of approximately RMB71.5 million for the same period in 2022, and (ii) a profit attributable to owners of the Company in the range of RMB63 million to RMB73 million for the six months ended June 30, 2023, representing an increase of 4.0% to 20.5% as compared to that of approximately RMB60.6 million for the same period in 2022. Such increase is primarily due to a significant increase in the profit contributed by the Group’s blood purification business.

The Company is in the process of preparing the unaudited consolidated financial results of the Group for the six months ended June 30, 2023. The information contained in this announcement is only based on a preliminary review of the unaudited consolidated management accounts of the Group and the information currently available to the Board and is not based on any figures or information which has been audited or reviewed by the Company's auditors. The Company expects to publish the unaudited consolidated financial results of the Group for the six months ended June 30, 2023 on or before August 31, 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
PW Medtech Group Limited
普华和顺集团公司
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, August 22, 2023

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.